Abbott Laboratories Corporation

Abbvie Inc.

Other

Abbott Gmbh & Co Kg

Abbvie Bahamas Limited

Andrew O Stewart

Pramila A Bhatia

Teodozyj Kolasa

Meena V Patel

Dee W Brooks

Anwer Basha

Clint D Brooks

Richard A Craig

Marlon D Cowart

Jeffrey J Rohde

Catherine M McCarty

Jerome F Daanen

Zhiren Xia

Jonathan G Martin

Lawrence A Black

Michael E Kort

Huaqing Liu

David Gunn

Daniel Joseph Kerkman

Steven P Latshaw

Stanley DiDomenico

Jorge D Brioni

Michael J Coghlan

Sherry L Nelson

George A Doherty

Steven Armen Boyd

Ming Clinton Yeung

James B Summers, Jr

Irene I Drizin

Gui-Dong Zhu

Richard J Perner

David M Stout

Xenia Beebe Searle

David L Arendsen

Wendy Lee

Qingwei I Zhang

Nicholas A Mort

James D Ratajczyk

Indrani W Gunawardana

Michael A Staeger

Daria Darczak

Jennifer C Freeman

Qingwei Zhang

Kraig Lartey

Kevin R Condroski

Chih-hung Lee

Helmut Mack

Xueqing Wang

Arthur Gomtsyan

Michael R Schrimpf

John R Koenig

Guo Zhu Zheng

Erol K Bayburt

Jimmie L Moore

Randy Bell

Mark A Matulenko

Kathleen Mortell

Henry Q Zhang

Michael J Rozema

Kenneth M Engstrom

Daniel P Larson

Robert G Maki

Michael F Jarvis

Teodozyji Kolasa

Ahmed A Hakeem

Chih-Hung Lee

Stanley Didomenico

Arthur R Gomtsyan

Victoria E Scott

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar, n, R, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Lactam acetamides as calcium channel blockers

The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), wherein L, R, R, R, R, R, R, Rand Rare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

(4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L, L, R, R, and Rare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers

Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers

Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar, Ar, L, L, n, R, R, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as calcium channel blockers

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Acetamides and benzamides that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and Bare as described in the specification.

Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction

Benzimidazoles that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B, are as described in the specification.

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently markered non-steroidal anti-inflammatory drugs (NSAIDs).

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention relates to the use of compounds of formula (I)for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Benzimidazoles that are useful in treating male sexual dysfunction

The present invention describes pyridazinone compounds of formula Iwhich are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

Growing community of inventors

Libertyville, IL, United States of America

Andrew O Stewart